Get the Stockscreener App
13.79
5.60%
0.675
Mineralys Therapeutics Inc stock is traded at $13.79, with a volume of 441.10K.
It is up +5.60% in the last 24 hours and up +35.72% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$13.11
Open:
$13.03
24h Volume:
441.10K
Relative Volume:
0.72
Market Cap:
$671.04M
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-5.0495
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
+31.34%
1M Performance:
+35.72%
6M Performance:
+17.72%
1Y Performance:
+9.96%
1-Day Range:
$12.77
$13.95
1-Week Range:
$10.19
$18.29
52-Week Range:
$8.241
$18.29
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.88 | 671.04M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.61 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.38 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.00 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.17 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.50 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat - MSN
Watkins Advises Mineralys Therapeutics on US$175 Million Underwritten Public Offering of Common Stock - Latham & Watkins LLP
Biotech Alert: Searches spiking for these stocks today - TipRanks
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Proficio Capital Partners LLC Purchases New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Prices $175 Million Share Offering -March 12, 2025 at 03:58 am EDT - Marketscreener.com
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire
Mineralys Therapeutics sets $13.50 share price for public offering - Investing.com
Mineralys Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock - Nasdaq
Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - StockTitan
Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test - DELCO.Today
(MLYS) Trading Advice - Stock Traders Daily
Mineralys launches $250 mln equity offering to fund blood pressure drug; shares dip - TradingView
Pa.-based biopharma company successfully completes two trials for hypertension drug - Pennsylvania Business Report
Mineralys sees stock surge on lorundrostat data - The Pharma Letter
Mineralys Therapeutics (NASDAQ:MLYS) Given Buy Rating at HC Wainwright - Defense World
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
MLYS stock touches 52-week high at $15.41 amid market optimism - Investing.com Australia
Goldman Sachs maintains buy on Mineralys stock, $24 target By Investing.com - Investing.com Australia
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts (NASDAQ:MLYS) - Seeking Alpha
Goldman Sachs maintains buy on Mineralys stock, $24 target - Investing.com India
Items Tagged with 'uncontrolled or resistant hypertension' - BioWorld Online
Mineralys Seeks First-To-Market Edge In Uncontrolled Hypertension - Scrip
Mineralys Therapeutics launches $250 million stock offering - Investing.com India
Mineralys Therapeutics announces $250M common stock offering - TipRanks
Mineralys Therapeutics launches $250 million stock offering By Investing.com - Investing.com UK
Mineralys Plans $250M Stock Offering to Fund Hypertension Drug Development - StockTitan
Sector Update: Health Care Stocks Decline Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Mineralys hits near two-year high as blood pressure drug meets trial goals - TradingView
Stifel maintains Buy on Mineralys Therapeutics, $45 target - Investing.com India
MLYS’s price-to-book ratio: An indicator of the company’s performance - US Post News
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate - Yahoo Finance
The Blood Pressure Breakthrough: Mineralys Therapeutics' Lorundrostat Shows Promise in Treating Uncontrolled Hypertension - RagingBull
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher - Benzinga
Mineralys’s stock soars as hypertension pill scores in two pivotal trials - Yahoo Finance
Stifel maintains Buy on Mineralys Therapeutics, $45 target By Investing.com - Investing.com South Africa
Mineralys surges 53% on pivotal data for hypertension asset lorundrostat - MSN
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Mineralys sees a double drop in blood pressure and a stock pop - BioWorld Online
Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes - TipRanks
Mineralys shares climb on study data for blood pressure drug - BioPharma Dive
Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc. - TipRanks
Mineralys' drug for persistent hypertension succeeds in two trials - TradingView
MLYS stock touches 52-week high at $15.41 amid market optimism By Investing.com - Investing.com South Africa
Mineralys Therapeutics stock soars on blood pressure drug data - STAT
Mineralys Therapeutics Shares Hit 52-Week High on Hypertension Study Results - MarketWatch
Mineralys (MLYS) Sees Strong Pre-Hour Growth After Promising Clinical Trial News - Stocks Telegraph
Lorundrostat shows promise in hypertension trials By Investing.com - Investing.com Australia
Mineralys Therapeutics Announces Positive Topline Results - GlobeNewswire
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levy Adam Scott | CFO and Secretary |
Jan 13 '25 |
Sale |
9.10 |
10,757 |
97,864 |
226,097 |
| Rodman David Malcom | Chief Medical Officer |
Jan 13 '25 |
Option Exercise |
0.84 |
11,367 |
9,567 |
158,172 |
| Congleton Jon | Chief Executive Officer |
Jan 13 '25 |
Sale |
9.06 |
18,333 |
166,082 |
877,608 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):